Literature DB >> 30877950

Cytokine profile of macrophage activation syndrome associated with Kawasaki disease.

Asumi Jinkawa1, Masaki Shimizu2, Keigo Nishida1, Shuya Kaneko1, Masaaki Usami1, Naoto Sakumura1, Hitoshi Irabu1, Maiko Takakuwa1, Natsumi Inoue1, Mao Mizuta1, Yasuhiro Ikawa1, Shuhei Fujita3, Akihiro Yachie1.   

Abstract

The present study aimed to assess the kinetics of cytokine release and compare the accuracy of serum biomarkers for the diagnosis of macrophage activation syndrome (MAS) associated with Kawasaki disease (KD). Serum neopterin, interleukin (IL)-18, IL-6 and soluble tumour necrosis factor receptor type I (sTNFR-I) and sTNFR-II levels were determined using enzyme-linked immunosorbent assay in 78 patients with KD, including five with MAS. Results were compared to the clinical features of MAS. Serum neopterin, IL-18, sTNFR-II levels and sTNFR-II/I ratio were significantly elevated in KD patients with MAS compared to those in the acute phase. Receiver operating characteristic curve analysis revealed areas under the curve and cutoff values of neopterin, IL-18, sTNFR-II levels and sTNFR-II/I ratio were 0.9750/30.0 nmol/L, 0.9813/1165 ng/mL, 0.9969/16,600 pg/mL and 0.9875/4.475, respectively. Serum sTNFR-II levels correlated positively with disease activity. These findings indicate that overproduction of interferon (IFN)-γ and TNF-α reflected by increased serum levels of neopterin and sTNFR-II are closely associated with the pathogenesis of MAS associated with KD. Serum sTNFR-II levels might be a useful marker to diagnose the transition to MAS.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Kawasaki disease; Macrophage activation syndrome; Soluble tumour necrosis factor receptor type II

Year:  2019        PMID: 30877950     DOI: 10.1016/j.cyto.2019.03.001

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  12 in total

1.  Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease.

Authors:  Ana Esteve-Sole; Jordi Anton; Rosa Maria Pino-Ramirez; Judith Sanchez-Manubens; Victoria Fumadó; Claudia Fortuny; María Rios-Barnes; Joan Sanchez-de-Toledo; Mónica Girona-Alarcón; Juan Manuel Mosquera; Silvia Ricart; Cristian Launes; Mariona Fernández de Sevilla; Cristina Jou; Carmen Muñoz-Almagro; Eva González-Roca; Andrea Vergara; Jorge Carrillo; Manel Juan; Daniel Cuadras; Antoni Noguera-Julian; Iolanda Jordan; Laia Alsina
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

Review 2.  Clinical perspectives and therapeutic strategies: pediatric autoinflammatory disease-a multi-faceted approach to fever of unknown origin of childhood.

Authors:  Akihiro Yachie
Journal:  Inflamm Regen       Date:  2022-07-02

3.  A Continuous Increase in CXC-Motif Chemokine Ligand 10 in a Case of Anti-Nuclear Matrix Protein-2-Positive Juvenile Dermatomyositis.

Authors:  Tsunehisa Nagamori; Emi Ishibazawa; Yoichiro Yoshida; Kengo Izumi; Masayuki Sato; Yuki Ichimura; Naoko Okiyama; Ichizo Nishino; Hiroshi Azuma
Journal:  J Med Cases       Date:  2022-06-02

Review 4.  Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.

Authors:  Lung Chang; Horng-Woei Yang; Tang-Yu Lin; Kuender D Yang
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

5.  Hepatic progenitor cell activation is induced by the depletion of the gut microbiome in mice.

Authors:  Fei Wang; Nan-Nan Sun; Lan-Lan Li; Wan-Wan Zhu; Jianbo Xiu; Yan Shen; Qi Xu
Journal:  Microbiologyopen       Date:  2019-05-16       Impact factor: 3.139

6.  Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child.

Authors:  Yohei Yamaguchi; Kei Takasawa; Hitoshi Irabu; Kanako Hiratoko; Yosuke Ichigi; Ko Hirata; Yumie Tamura; Miki Murakoshi; Motoi Yamashita; Hisae Nakatani; Masuhiro Shimoda; Taku Ishii; Tomohiro Udagawa; Masaki Shimizu; Hirokazu Kanegane; Tomohiro Morio
Journal:  J Infect Chemother       Date:  2022-01-24       Impact factor: 2.065

Review 7.  Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison.

Authors:  Chetan Sharma; Madhusudan Ganigara; Caroline Galeotti; Joseph Burns; Fernando M Berganza; Denise A Hayes; Davinder Singh-Grewal; Suman Bharath; Sujata Sajjan; Jagadeesh Bayry
Journal:  Nat Rev Rheumatol       Date:  2021-10-29       Impact factor: 20.543

8.  The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.

Authors:  J M Krei; H J Møller; J B Larsen
Journal:  Clin Exp Immunol       Date:  2020-11-23       Impact factor: 4.330

9.  Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.

Authors:  Pinar Ataca Atilla; Mary K McKenna; Haruko Tashiro; Madhuwanti Srinivasan; Feiyan Mo; Norihiro Watanabe; Brian Wesley Simons; Alexandra McLean Stevens; Michele S Redell; Helen E Heslop; Maksim Mamonkin; Malcolm K Brenner; Erden Atilla
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

10.  Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.

Authors:  Caroline Diorio; Sarah E Henrickson; Laura A Vella; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Cristina Jasen; Fran Balamuth; David M Barrett; Brenda L Banwell; Kathrin M Bernt; Allison M Blatz; Kathleen Chiotos; Brian T Fisher; Julie C Fitzgerald; Jeffrey S Gerber; Kandace Gollomp; Christopher Gray; Stephan A Grupp; Rebecca M Harris; Todd J Kilbaugh; Audrey R Odom John; Michele Lambert; Emily J Liebling; Michele E Paessler; Whitney Petrosa; Charles Phillips; Anne F Reilly; Neil D Romberg; Alix Seif; Deborah A Sesok-Pizzini; Kathleen E Sullivan; Julie Vardaro; Edward M Behrens; David T Teachey; Hamid Bassiri
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.